arrow
M

María José Casanova

Universidad Autonoma de Madrid
H指数:22
被引数:2,537

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease

新诊断炎症性肠病患者生物制剂治疗、住院及手术的临床过程与预测因素:一项为期五年的前瞻性研究

2026-10-110
OA
Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry

炎症性肠病未分类患者的结局与再分类模式:一项与西班牙ENEIDA登记系统中溃疡性结肠炎患者匹配的多中心研究

2026-09-230
OAAI
Evaluation of Long-Term Outcomes of Crohn’s Disease Complicated by Intra-Abdominal Abscess: A Retrospective International Cohort Study

克罗恩病合并腹腔脓肿的长期结局评估:一项回顾性国际队列研究

2026-04-060
OA
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

溃疡性结肠炎中JAK抑制剂的序贯治疗:同类别转换治疗的有效性与安全性

2025-11-030
PRE
Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages

丁酸盐主要通过抑制单核细胞和巨噬细胞中的HDAC3来抑制炎症性肠病的黏膜炎症。

2025-10-190
OAAI
International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements

关于妊娠和哺乳期炎症性肠病管理的国际胃肠病学家调查:现状与改进的必要性

2025-10-140
OAAI
Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers

新诊断炎症性肠病患者的全面蛋白质组学分析:潜在生物标志物的鉴定

2025-10-010
PRE
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry
2025-06-130
OAAI
Multi-Omics Biomarkers for Predicting Therapeutic Efficacy in Inflammatory Bowel Disease: Advancing Towards Tailored Treatments
2025-01-220
PRE
Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
2025-01-220
PRE
Comparing JAK inhibitors in ulcerative colitis: which one truly leads in the real world? Results from the ENEIDA registry of GETECCU
2025-01-220
PRE
Identification of metabolic predictive biomarkers of response to Inflammatory Bowel Disease treatment
2025-01-220
PRE
Prevalence, clinical and anorectal function characterization of faecal incontinence and rectal urgency in ulcerative colitis patients (HOPE Study)
2025-01-220
PRE
Impact of prenatal and breastfeeding exposure to biologic drugs on the first-year anthropometric development of infants born to mothers with inflammatory bowel disease from DUMBO registry of GETECCU
2025-01-220
PRE